Cited by 62Genetic and Clinical Aspects of Sex Determination and Chromosomal AbnormalitiesMenopause: Health Impacts and TreatmentsSexual Differentiation and Disorders

Sex hormone replacement therapy in Turner syndrome—impact on morbidity and mortality

Open access
Viuff, Mette H, Berglund, Agnethe, Juul, Svend, Andersen, Niels H, Stochholm, Kirstine, Gravholt, Claus H·2020·The Journal of Clinical Endocrinology & Metabolism

Abstract

CONTEXT: The long-term effects of female hormone replacement therapy (HRT) in Turner syndrome (TS) are unknown. OBJECTIVE: To examine morbidity, mortality and medicinal use in TS and the impact of HRT in 45,X women. DESIGN AND SETTING: National cohort study, following all TS individuals ever diagnosed in Denmark from 1977 to 2014. PATIENTS AND METHODS: In the Danish Cytogenetic Central Registry, we identified 1156 females diagnosed with TS from 1960 to 2014, and, subsequently, Statistics Denmark randomly identified 115 577 age-matched female controls. TS women and their matched controls were linked with person-level data from the National Patient Registry and the Medication Statistics Registry, and they were compared concerning mortality, hospitalizations, and medical prescriptions. Among 329 45,X women, 44 had never been HRT treated, and 285 had been treated at some point. HRT treated women were compared with untreated concerning mortality, hospitalizations, and medical prescriptions. RESULTS: Endocrine and cardiovascular mortality and morbidity were significantly increased in TS compared with the matched controls. Comparing HRT treated with nontreated 45,X women, we found a similar mortality (hazard ratio 0.83, 95% confidence interval 0.38-1.79). Among the HRT-treated 45,X women, we found a significantly lower use of antihypertensives, antidiabetics, and thyroid hormones and significantly reduced hospitalization rates for stroke and osteoporotic fractures. CONCLUSION: Women with TS have an increased overall mortality and morbidity. HRT seems to have a beneficial effect on endocrine conditions, hypertension, and stroke in women with 45,X karyotype, with no clear impact on mortality.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/clinem/dgz039

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Viuff, M. H., Berglund, A., Juul, S., Andersen, N. H., Stochholm, K., & Gravholt, C. H.
Affiliations
  • Aarhus University Hospital (DK)
  • Aarhus University (DK)
  • Aalborg University Hospital (DK)
Corresponding author
Viuff, Mette H
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2019-09-23
Volume
105
Issue
2
Pages
468-478
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2976117252
Cited by
62
References
53
Citations by year
2026: 5 · 2025: 10 · 2024: 8 · 2023: 11 · 2022: 14 · 2021: 7 · 2020: 6 · 2019: 1
FWCI
4.22
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • SSRN Electronic Journal (publishedVersion)
  • PubMed (publishedVersion)
  • Scopus (Elsevier) (submittedVersion)
  • VBN Forskningsportal (Aalborg Universitet) (submittedVersion)
Funders
  • Aarhus University
  • Novo Nordisk Foundation (NNF13OC0003234, NNF15OC0016474)
  • Familien Hede Nielsen foundation
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sexual Differentiation and Disorders
Keywords
Turner syndrome, sex hormone replacement therapy, mortality, morbidity, 45,X karyotype, cardiovascular mortality, stroke, osteoporotic fractures, hypertension, antihypertensive medication use, hospitalization, long-term outcomes
MeSH terms
Adolescent, Adult, Aged, Aged, 80 and over, Cardiovascular Diseases, Child, Child, Preschool, Denmark, Endocrine System Diseases, Female, Hospitalization, Humans, Infant, Infant, Newborn, Middle Aged, Morbidity, Registries, Turner Syndrome, Hormone Replacement Therapy, Prescriptions, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review